Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANGEL R CHINEA

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1720029317
CMS profile
32963
Location
GUAYNABO, PR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$246,085.30

281 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
EMD Serono, Inc. $127,266.88 80
Biogen, Inc. $39,740.69 52
Genentech USA, Inc. $23,696.55 21
Horizon Therapeutics plc $17,491.99 15
AbbVie Inc. $15,819.61 20
NOVARTIS PHARMACEUTICALS CORPORATION $7,119.92 41
E.R. Squibb & Sons, L.L.C. $6,047.83 20
Alexion Pharmaceuticals, Inc. $5,508.66 6
BANNER LIFE SCIENCES, LLC $1,096.79 5
Alphatec Spine, Inc $1,069.75 3
Stryker Corporation $306.88 2
Celgene Corporation $300.00 1
GENZYME CORPORATION $179.03 4
NuVasive, Inc. $159.43 2
TG Therapeutics, Inc. $115.34 1
ANI Pharmaceuticals, Inc. $110.76 5
PBG PUERTO RICO LLC $55.19 3

Page 2 of 6; records 51–100 of 281 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANGEL R CHINEA

NPI 1720029317 · CMS profile ID 32963

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

GUAYNABO, PR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 6; records 51–100 of 281 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1720029317?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANGEL R CHINEA, NPI 1720029317, CMS profile ID 32963. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 281 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1720029317?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). ANGEL R CHINEA, NPI 1720029317, CMS profile ID 32963. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 281 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1720029317?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
ANGEL R CHINEA, NPI 1720029317, CMS profile ID 32963, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 6; records 51–100 of 281 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1720029317?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

281 matching records · $246,085.30 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 281 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 281.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $2.5010/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015620677 CMS
EMD Serono, Inc. $63.2510/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032558223 CMS
EMD Serono, Inc. $57.6010/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032567589 CMS
EMD Serono, Inc. $77.9510/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1119753124 CMS
EMD Serono, Inc. $33.5310/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032396681 CMS
EMD Serono, Inc. $77.9410/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1119753066 CMS
EMD Serono, Inc. $70.2510/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032396673 CMS
AbbVie Inc. $1,500.0010/09/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996425437 CMS
EMD Serono, Inc. $53.9410/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032396717 CMS
Biogen, Inc. $11.5010/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012279905 CMS
Novartis Pharmaceuticals Corporation $72.2910/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991442087 CMS
EMD Serono, Inc. $34.4009/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032402429 CMS
Horizon Therapeutics plc $200.0009/28/2023 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 986972081 CMS
PBG PUERTO RICO LLC $24.0809/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049172077 CMS
Biogen, Inc. $6.1109/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012209429 CMS
E.R. Squibb & Sons, L.L.C. $25.0009/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015620637 CMS
EMD Serono, Inc. $76.5209/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032396749 CMS
Novartis Pharmaceuticals Corporation $6.4709/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991442071 CMS
Alphatec Spine, Inc $372.0009/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1007112987 CMS
Novartis Pharmaceuticals Corporation $6.2009/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991442067 CMS
Novartis Pharmaceuticals Corporation $24.3809/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991442083 CMS
Biogen, Inc. $49.5009/13/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012136301 CMS
Biogen, Inc. $60.0009/13/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012148761 CMS
Biogen, Inc. $60.0009/13/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012251391 CMS
Biogen, Inc. $20.5309/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012151783 CMS
Novartis Pharmaceuticals Corporation $3.2509/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991442051 CMS
Genentech USA, Inc. $6.2109/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040298805 CMS
Biogen, Inc. $4,904.0009/06/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012142271 CMS
Biogen, Inc. $96.2909/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012279069 CMS
Novartis Pharmaceuticals Corporation $2.2809/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991442047 CMS
Novartis Pharmaceuticals Corporation $80.1009/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991442063 CMS
EMD Serono, Inc. $98.6709/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032368065 CMS
EMD Serono, Inc. $9,603.0009/01/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032409529 CMS
EMD Serono, Inc. $4,593.0009/01/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032411553 CMS
Novartis Pharmaceuticals Corporation $64.4508/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991442059 CMS
EMD Serono, Inc. $96.9408/30/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032407173 CMS
EMD Serono, Inc. $101.3808/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032456455 CMS
EMD Serono, Inc. $74.8008/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032424435 CMS
Novartis Pharmaceuticals Corporation $76.5408/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991442055 CMS
Novartis Pharmaceuticals Corporation $113.5508/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991864897 CMS
Novartis Pharmaceuticals Corporation $9.4108/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991442043 CMS
E.R. Squibb & Sons, L.L.C. $2.1208/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015620613 CMS
NuVasive, Inc. $23.0608/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049550177 CMS
NuVasive, Inc. $136.3708/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049550203 CMS
GENZYME CORPORATION $77.4708/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049811131 CMS
Biogen, Inc. $77.3308/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012268619 CMS
Biogen, Inc. $27.9308/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012253581 CMS
Biogen, Inc. $9.4308/14/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012121889 CMS
EMD Serono, Inc. $378.0008/11/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032407609 CMS
EMD Serono, Inc. $49.2408/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032553595 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $317,786.33 403
PY2020 $185,726.05 245
PY2021 $196,275.82 300
PY2022 $279,334.72 321
PY2023 $246,085.30 281
PY2024 $248,405.51 268
PY2025 $266,405.69 279

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $6,684.96 3
PY2025 Principal investigator $1,907,962.24 33
PY2024 Principal investigator $2,078,888.10 19
PY2023 Recipient $1,351.01 1
PY2023 Principal investigator $2,399,942.64 26
PY2022 Recipient $6,147.00 5
PY2022 Principal investigator $2,541,163.26 22
PY2021 Recipient $673.00 2
PY2021 Principal investigator $1,098,425.63 28
PY2020 Principal investigator $432,608.52 30
PY2019 Recipient $2,838.49 7
PY2019 Principal investigator $1,131,727.12 18

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

36 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 TG Therapeutics, Inc. $17,700.00 11/30/2025 Non-covered Recipient Entity
Caribbean Center For Clinical Research
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200235
Recipient Novartis Pharmaceuticals Corporation $509.29 11/07/2025 Covered Recipient Physician Research Publication/ Writing Support No dispute reported 06/30/2026 1190291303
Principal investigator 1 TG Therapeutics, Inc. $24,250.00 11/01/2025 Non-covered Recipient Entity
Caribbean Center For Clinical Research
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200233
Principal investigator 1 TG Therapeutics, Inc. $5,450.00 09/30/2025 Non-covered Recipient Entity
Caribbean Center For Clinical Research
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200207
Principal investigator 1 EMD Serono, Inc. $345.00 09/24/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240117939
Principal investigator 1 EMD Serono, Inc. $978.00 09/22/2025 Non-covered Recipient Entity
Caribbean Center for Clinical
A Multicenter, Observational Study to Characterize the Clinical Course in a Real-World, US Cohort of Patients with Relapsing Multiple Sclerosis of Advanced Age (>50 years) Treated with Cladribine Tablets (AGING Study) No dispute reported 06/30/2026 1240118221
Principal investigator 1 TG Therapeutics, Inc. $20,600.00 08/31/2025 Non-covered Recipient Entity
Caribbean Center For Clinical Research
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200205
Principal investigator 1 Genentech, Inc. $11,673.00 08/22/2025 Non-covered Recipient Entity
CARIBBEAN CENTER FOR CLINICAL RESEARCH
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211583833
Principal investigator 1 TG Therapeutics, Inc. $7,525.00 07/31/2025 Non-covered Recipient Entity
Caribbean Center For Clinical Research
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200203
Principal investigator 1 TG Therapeutics, Inc. $4,198.50 07/31/2025 Non-covered Recipient Entity
The University of Texas at Austin
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200525
Recipient Novartis Pharmaceuticals Corporation $3,370.12 07/30/2025 Covered Recipient Physician COMB157GUS07 No dispute reported 06/30/2026 1190292535
Principal investigator 1 Celgene Corporation $5,344.00 06/25/2025 Non-covered Recipient Entity
Caribbean Center For Clinical Research Inc
A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063) No dispute reported 06/30/2026 1222306473
Principal investigator 1 Novartis Pharmaceuticals Corporation $574,505.94 06/24/2025 Non-covered Recipient Entity
CARIBBEAN CENTER FOR CLINICAL RESEARCH, INC
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190306921
Principal investigator 1 EMD Serono, Inc. $20,293.00 06/23/2025 Non-covered Recipient Entity
Caribbean Center for Clinical
A Multicenter, Observational Study to Characterize the Clinical Course in a Real-World, US Cohort of Patients with Relapsing Multiple Sclerosis of Advanced Age (>50 years) Treated with Cladribine Tablets (AGING Study) No dispute reported 06/30/2026 1240118214
Principal investigator 1 Genentech, Inc. $20,157.30 06/19/2025 Non-covered Recipient Entity
CARIBBEAN CENTER FOR CLINICAL RESEARCH
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211583822
Recipient Novartis Pharmaceuticals Corporation $2,805.55 06/03/2025 Covered Recipient Physician Research Publication/Writing Support No dispute reported 06/30/2026 1190291676
Principal investigator 1 TG Therapeutics, Inc. $36,750.00 06/01/2025 Non-covered Recipient Entity
Caribbean Center For Clinical Research
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200167
Principal investigator 1 EMD Serono, Inc. $22,598.00 05/26/2025 Non-covered Recipient Entity
Caribbean Center for Clinical
A Multicenter, Observational Study to Characterize the Clinical Course in a Real-World, US Cohort of Patients with Relapsing Multiple Sclerosis of Advanced Age (>50 years) Treated with Cladribine Tablets (AGING Study) No dispute reported 06/30/2026 1240118217
Principal investigator 1 EMD Serono, Inc. $1,345.00 05/22/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240117943
Principal investigator 1 Genentech, Inc. $5,947.20 04/17/2025 Non-covered Recipient Entity
CARIBBEAN CENTER FOR CLINICAL RESEARCH
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211583827
Principal investigator 1 TG Therapeutics, Inc. $41,525.00 03/31/2025 Non-covered Recipient Entity
Caribbean Center For Clinical Research
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200165
Principal investigator 1 EMD Serono, Inc. $300.00 03/24/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240117947
Principal investigator 1 EMD Serono, Inc. $1,280.00 03/24/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240117951
Principal investigator 1 Hoffmann-La Roche Limited $4,659.30 03/12/2025 Non-covered Recipient Entity
CARIBBEAN CENTER FOR CLINICAL
Satralizumab open label treatment study in patients with NMOSD No dispute reported 06/30/2026 1211583806
Principal investigator 1 Hoffmann-La Roche Limited $658.75 03/12/2025 Non-covered Recipient Entity
CARIBBEAN CENTER FOR CLINICAL
Satralizumab open label treatment study in patients with NMOSD No dispute reported 06/30/2026 1211583811
Principal investigator 1 Hoffmann-La Roche Limited $3,507.10 03/12/2025 Non-covered Recipient Entity
CARIBBEAN CENTER FOR CLINICAL
Satralizumab open label treatment study in patients with NMOSD No dispute reported 06/30/2026 1211583815
Principal investigator 1 Genentech, Inc. $2,073.60 03/05/2025 Non-covered Recipient Entity
CARIBBEAN CENTER FOR CLINICAL RESEARCH
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211583818
Principal investigator 1 TG Therapeutics, Inc. $52,850.00 02/28/2025 Non-covered Recipient Entity
Caribbean Center For Clinical Research
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200163
Principal investigator 1 Novartis Pharmaceuticals Corporation $315.88 02/10/2025 Non-covered Recipient Entity
CARIBBEAN CENTER FOR CLINICAL RESEARCH, INC
A phase IV, prsopective, multicenter, open-label, mother-milk study to evaluate ofatumumab concentration in the breast milk of lactating women with Relapsing forms of Multiple Sclerosis (RMS) receving kesimpta (ofatumumab) No dispute reported 06/30/2026 1190306917
Principal investigator 1 TG Therapeutics, Inc. $1,300.00 02/01/2025 Non-covered Recipient Entity
Caribbean Center For Clinical Research
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200161
Principal investigator 1 Genentech, Inc. $7,793.00 01/29/2025 Non-covered Recipient Entity
CARRIBEAN CENTER FOR CLINICAL RESEARCH 18374
Ocrevus Subcutaneous Study for Safety and Tolerability No dispute reported 06/30/2026 1211584000
Principal investigator 1 Genentech, Inc. $3,000.00 01/29/2025 Non-covered Recipient Entity
CARRIBEAN CENTER FOR CLINICAL RESEARCH 18374
Ocrevus Subcutaneous Study for Safety and Tolerability No dispute reported 06/30/2026 1211584005
Principal investigator 1 Novartis Pharmaceuticals Corporation $33,320.09 01/07/2025 Non-covered Recipient Entity
CARIBBEAN CENTER FOR CLINICAL RESEARCH, INC
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190306915
Principal investigator 1 Novartis Pharmaceuticals Corporation $961,629.58 01/06/2025 Non-covered Recipient Entity
CARIBBEAN CENTER FOR CLINICAL RESEARCH, INC
AGNOS: An 18-month, Open-label, Multi-Center Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Nave, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes No dispute reported 06/30/2026 1190306919
Principal investigator 1 TG Therapeutics, Inc. $13,250.00 01/06/2025 Non-covered Recipient Entity
Caribbean Center For Clinical Research
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200159
Principal investigator 1 Novartis Pharmaceuticals Corporation $840.00 01/01/2025 Non-covered Recipient Entity
THE SAN JORGE HOSPITAL, INC
A two year double blind randomized multicenter active controlled study to evaluate the safety and efficacy of fingolimod administered orally once daily versus interferon beta 1a i m once weekly in pediatric patients with relapsing remitting multiple scler No dispute reported 06/30/2026 1190302077